Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Total 13F shares
-
9,156,533
-
Share change
-
-165,156
-
Total reported value
-
$25,870,000
-
Price per share
-
$2.83
-
Number of holders
-
30
-
Value change
-
-$498,228
-
Number of buys
-
13
-
Number of sells
-
8
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2017
As of 31 Dec 2017,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,156,533 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, ORBIMED ADVISORS LLC, Schonfeld Strategic Advisors LLC, DAFNA Capital Management LLC, Tekla Capital Management LLC, Invesco Private Capital, Inc., SABBY MANAGEMENT, LLC, Point72 Asset Management, L.P., and Alyeska Investment Group, L.P..
This page lists
31
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.